Pipeline

Clinical
Product Trial Targeted Indications Product
Development
Pre-Clinical Phase I Phase II Phase III
EBVST TT10 Nasopharyngeal Cancer
Armored HPVST TT12 Cervical Cancer & Oropharyngeal Cancer
Pre-Clinical
Product Trial Targeted Indications Product
Development
Pre-Clinical Phase I Phase II Phase III
GPC3-CAR VST TT14 GPC3 Positive Solid Tumors
HER2-CAR VST + CAdVEC TT16 HER2 Positive Solid Tumors
Clinical
Product / Targeted Indications Trail Product
Dev
Pre-Clinical Phase I Phase II Phase III
EBVST / Nasopharyngeal Cancer TT10
Armored HPVST / Cervical Cancer & Oropharyngeal Cancer TT12
Pre-Clinical
Product / Targeted Indications Trail Product
Dev
Pre-Clinical Phase I Phase II Phase III
GPC3-CAR VST / GPC3 Positive Solid Tumors TT14
HER2-CAR VST + CAdVEC / HER2 Positive Solid Tumors TT16

Indications

Epstein-Barr Virus-Specific T Cells (EBVSTs) for Nasopharyngeal Cancer (NPC)

Using our proprietary Virus-Specific T cell (VST) platform, we are able to target specific Epstein-Barr Virus (EBV) proteins that are present on EBV-positive tumors.

Our EBVSTs extracted from patient’s blood are enhanced for anti-tumor potency, selectively activated and expanded ex vivo before infusion back into the patient

Trial Name:

TT10: NPC EBVST (Phase III)

Indication: Nasopharyngeal cancer (NPC)
US FDA Orphan Drug and Fast Track Designation

Enrollment Status: Recruiting

Trial Number: NCT02578641

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial of Gemcitabine and Carboplatin Followed by Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal cancer Patients.

Learn more at Clinicaltrials.gov

Locations

United States

  • California, United States
  • Massachusetts, United States
  • Texas, United States

Malaysia

Singapore

Taiwan

Thailand

Human Papillomavirus-Specific T Cells (HPVSTs) for Cervical and Oropharyngeal Cancer

We have extended our proprietary VST platform to treat other virus-associated cancers. Cervical cancer and oropharyngeal cancer are strongly associated with human papillomavirus (HPV) infection. To increase durability in the tumor microenvironment, HPVSTs are armored with a mutant TGF-β receptor, to counter the suppressive effects of TGF-β, a cytokine commonly secreted in the tumor microenvironment.

HPVSTs are Selected and Expanded From Patient’s Blood

Trial Name:

TT12: CC-OPC HPVST (Phase I)

Indication: Cervical Cancer and Oropharyngeal Cancer

Enrollment Status: Recruiting

Trial Number: NCT02379520

Study evaluating HPV-16/18 E6/E7-Specific T Lymphocytes in patients with Relapsed HPV-Associated Cancers

Learn more at Clinicaltrials.gov

Locations

United States, Texas

Glypican-3 (GPC3) CAR VSTs for Solid Tumors

Tessa has developed a proprietary GPC3-Chimeric Antigen Receptor (CAR) construct which enables the targeting of GPC3-positive tumors.

GPC3-CAR VST Selectively Kills GPC3+ Tumors

GPC3-CAR VSTs travel to the tumor site, where they selectively bind to GPC3 on the surface of the tumor. This binding induces VST signaling leading to the release of cytotoxic granules enabling effective tumor killing.

HER2-CAR VSTs + Oncolytic & Helper Adenovirus for Head & Neck Cancer

Human Epidermal Growth Factor Receptor (HER2) is over expressed in multiple solid tumors, including breast cancer, bladder cancer and head and neck. The overexpression of HER2 is an indicator of poor prognosis, increased recurrence and decreased OS. Our therapy is a two step process, firstly the adenoviruses are infused into the patient followed by HER2-CAR VSTs.

Oncolytic Adenovirus

Selectively replicates and kills tumor cells

Helper-dependent Adenovirus

Expresses the checkpoint inhibitor
PD-L1 and IL-12

HER2-specific CAR VST

Targets and kills HER2 expressing tumor cells